Retatrutide is an investigational injectable therapy that acts on three hormone pathways (GLP-1, GIP and glucagon) — a “next-generation” approach that has shown promising early results in weight-management and metabolic studies. At present, Retatrutide is not approved for clinical use in the UK. It remains under evaluation and cannot legally be prescribed or supplied outside authorised clinical trials. Because of this — and because unregulated, illegal products claiming to be “Retatrutide” have recently been seized by regulators in the UK — we strongly advise against attempting to source it from any non-approved pharmacy or online vendor.

When might it become available in the UK?

Forecasts from credible sources suggest if all goes well with the ongoing trials, Retatrutide could potentially become available for prescription in the UK during 2026–2027 — pending approval by regulatory bodies.

What this means for our clinic and our patients

We are keeping a close and careful eye on the development of Retatrutide. As soon as it receives official approval, we will assess whether it is suitable for introduction into our weight-management programme. Until then, we will continue offering our established, approved treatments. We are committed to keeping our patients informed — updates will be posted here on our website and communicated directly. If you have any questions about current supported treatment options, feel free to contact our clinical team; we are happy to advise on safe, approved pathways for weight management